Short Term Traders-Listed Stocks

[matt24d]

CYCC, Means nothing Read the whole PR,

"Cyclacel Receives Complaint Filed by Celgene Seeking to Avoid Certain Cyclacel Patents

BERKELEY HEIGHTS, N.J., April 30, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it received a complaint filed by Celgene Corporation seeking a declaration from the court that four Cyclacel-owned patents, which claim the use of romidepsin injection in T-cell lymphomas, are not infringed by Celgene's products and are invalid. Cyclacel and its counsel have not had an opportunity to thoroughly review these filings.

The four patents cited in the complaint do not involve Cyclacel's clinical development candidates nor its commercial products.